GAD-7 Calculator

What is the GAD-7?

The Generalised Anxiety Disorder 7-item Scale (GAD-7) is a brief, validated self-report questionnaire designed to assess the severity of generalised anxiety symptoms over the preceding two weeks. Developed by Drs Robert L. Spitzer, Kurt Kroenke, Janet B.W. Williams, and Bernd Löwe, the GAD-7 was first published in the Archives of Internal Medicine in 2006.

Each of the seven items is scored from 0 ("Not at all") to 3 ("Nearly every day"), producing a total score between 0 and 21. The GAD-7 is one of the most widely used anxiety screening instruments in clinical practice and research worldwide, and is freely available in the public domain.

Development and Validation

The GAD-7 was developed using criteria from the DSM-IV for generalised anxiety disorder, with items refined through iterative testing in a primary care population of 2,740 patients. The original validation study demonstrated excellent internal consistency (Cronbach's alpha of 0.92) and good test-retest reliability (intraclass correlation of 0.83).

At a cut-off score of 10, the GAD-7 showed a sensitivity of 89% and specificity of 82% for generalised anxiety disorder. The instrument also demonstrated moderate to good sensitivity for detecting panic disorder, social anxiety disorder, and post-traumatic stress disorder, making it useful as a general anxiety screening measure.

Subsequent validation studies across diverse populations and languages have consistently supported the reliability and validity of the GAD-7. A 2016 systematic review and diagnostic meta-analysis by Plummer et al. in General Hospital Psychiatry confirmed its strong diagnostic accuracy across multiple settings.

How GAD-7 Scoring Works

The GAD-7 uses a straightforward additive scoring approach. Each item is rated on a four-point scale:

0 = Not at all 1 = Several days 2 = More than half the days 3 = Nearly every day

Total scores range from 0 to 21. Published severity thresholds are:

0–4: Minimal anxiety 5–9: Mild anxiety 10–14: Moderate anxiety 15–21: Severe anxiety

A score of 10 or above is commonly used as the threshold suggesting further clinical evaluation may be beneficial. Scores of 5, 10, and 15 represent the cut-points for mild, moderate, and severe anxiety, respectively.

Clinical Applications

The GAD-7 is used in clinical settings for screening, severity assessment, and outcome monitoring. Its brevity (typically completed in under two minutes) makes it practical for routine use in busy primary care, psychology, psychiatry, and allied health settings.

The instrument is particularly valuable for tracking symptom changes over time. Research has estimated that a change of approximately 4 points on the GAD-7 represents a clinically meaningful difference. This makes it useful for monitoring progress during the course of clinical care.

The GAD-7 is frequently paired with the PHQ-9 depression measure, as anxiety and depression commonly co-occur. Together, these two instruments provide a brief but comprehensive picture of common mental health difficulties.

GAD-7 in Australian Practice

In Australia, the GAD-7 is widely used across primary care and mental health settings. It is listed as a recommended outcome measure under the Better Access program and is included in clinical guidelines published by the RANZCP.

Australian psychologists, psychiatrists, GPs, and counsellors use the GAD-7 as part of routine clinical assessment and outcome monitoring. It is commonly administered alongside the PHQ-9 to screen for the two most prevalent mental health conditions in the Australian population.

Australian community reference data are available from Stocker and colleagues' national survey of 13,829 Australian adults during the COVID-19 period (Psychiatry Research, 2021), supporting the standard 5/10/15 severity cut-points in Australian populations.

The instrument's availability in multiple languages supports its use with Australia's culturally and linguistically diverse population. Its widespread adoption in Australian primary care research underscores its acceptance in Australian clinical contexts.